Onconova Therapeutics Inc.

229 articles about Onconova Therapeutics Inc.

• Onconova Therapeutics to Present at the Guggenheim Oncology Conference

  2/2/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company will be participating in the Guggenheim Oncology Conference taking place virtually February 9, 2022, through February 11, 2022.

• Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

  1/4/2022

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10, 2022, through January 13, 2022.

• Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development

  12/13/2021

  Onconova Therapeutics, Inc. today announced that Dr. Adar Makovski Silverstein has joined Onconova as Director, Corporate Development.

• Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma

  12/2/2021

  Onconova Therapeutics, Inc. announced that early preliminary data from an investigator-initiated Phase 2 open label trial of rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa were presented at the Austrian Society of Dermatology and Venerology Annual Conference 2021, which took place from November 25 – 27, 2021.

• Onconova Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/22/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 29, 2021 through December 2, 2021.

• Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business UpdateConference call and live webcast at 4:30 p.m. ET today

  11/11/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended September 30, 2021, and provided a business update.

• Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2021 Financial Results on November 11, 2021Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 11

  11/4/2021

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its third quarter 2021 financial results on Thursday, November 11, 2021.

• Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF)

  9/29/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will be attending the upcoming virtual Sachs 21st Annual Biotech in Europe Forum (BEF) on October 7th and 8th 2021, and will be available for 1x1 meetings from Monday, October 4th through Friday, October 8th. 

• Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock

  9/28/2021

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced the closing of its previously announced underwritten public offering.

• Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock

  9/24/2021

  Onconova Therapeutics, Inc. today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $4.20 per share.

• Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - Sep 23, 2021

  9/23/2021

  Onconova Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel products to treat cancer, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

• Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

  9/22/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC).

• Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit

  9/20/2021

  Onconova Therapeutics, Inc. today announced an upcoming presentation at the 3rd Annual RAS Targeted Drug Development Summit

• Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

  9/9/2021

  Onconova Therapeutics, Inc. today announced that the Company will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021.

• Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateConference call and live webcast at 4:30 p.m. ET today

  8/12/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended June 30, 2021 and provided a business update.

• Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021

  8/5/2021

  Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its second quarter 2021 financial results on Thursday, August 12, 2021.

• Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer

  6/28/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC).

• Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement - June 22, 2021

  6/22/2021

  Onconova Therapeutics, Inc. announced that on June 17, 2021 it received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550, as the Company’s common stock had a closing bid price of at least $1.00 per share for 18 consecutive business days, from May 21, 2021 to June 16, 2021.

• Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade

  6/17/2021

  Onconova Therapeutics, Inc. today announced the publication of a preclinical study in the journal Molecular Cancer.

• Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium

  6/10/2021

  Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.